Brian R Untch
Overview
Explore the profile of Brian R Untch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Instrum R, Swartzwelder C, Ghossein R, Xu B, Givi B, Wong R, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075589
Background: Molecular assays serve as a potential risk stratification tool for cytologically indeterminate thyroid nodules (ITNs). mutations are nearly always associated with thyroid cancer. However, the malignancy risk for ITNs...
2.
Krishnamoorthy G, Glover A, Untch B, Sigcha-Coello N, Xu B, Vukel D, et al.
J Exp Med
. 2025 Feb;
222(5).
PMID: 39992626
RBM10 modulates transcriptome-wide cassette exon splicing. Loss-of-function RBM10 mutations are enriched in thyroid cancers with distant metastases. Analysis of transcriptomes and genes mis-spliced by RBM10 loss showed pro-migratory and RHO/RAC...
3.
Tiedje V, Vela P, Yang J, Untch B, Boucai L, Stonestrom A, et al.
bioRxiv
. 2024 Oct;
PMID: 39415999
Anaplastic thyroid cancer (ATC) is a clinically aggressive malignancy with a dismal prognosis. Combined BRAF/MEK inhibition offers significant therapeutic benefit in patients with -mutant ATCs. However, relapses are common and...
4.
Nigam A, Krishnamoorthy G, Chatila W, Berman K, Saqcena M, Walch H, et al.
Oncogene
. 2024 Aug;
43(37):2806-2819.
PMID: 39152269
In the clinical development of farnesyltransferase inhibitors (FTIs) for HRAS-mutant tumors, responses varied by cancer type. Co-occurring mutations may affect responses. We aimed to uncover cooperative genetic events specific to...
5.
Krishnamoorthy G, Glover A, Untch B, Sigcha-Coello N, Xu B, Vukel D, et al.
bioRxiv
. 2024 Jul;
PMID: 39026820
RBM10 modulates transcriptome-wide cassette exon splicing. Loss-of-function mutations are enriched in thyroid cancers with distant metastases. Analysis of transcriptomes and genes mis-spliced by RBM10 loss showed pro-migratory and RHO/RAC signaling...
6.
Sfreddo H, Koh E, Zhao K, Swartzwelder C, Untch B, Marti J, et al.
Thyroid
. 2024 Feb;
34(4):450-459.
PMID: 38407967
Genomic profiling is now available for risk stratification of cytologically indeterminate thyroid nodules (ITNs). Mutations in genes (, , ) are found in both benign and malignant thyroid nodules, although...
7.
Aksoy Y, Xu B, Viswanathan K, Ahadi M, Al Ghuzlan A, Alzumaili B, et al.
Histopathology
. 2024 Jan;
84(6):947-959.
PMID: 38253940
Aims: Recently, there have been attempts to improve prognostication and therefore better guide treatment for patients with medullary thyroid carcinoma (MTC). In 2022, the International MTC Grading System (IMTCGS) was...
8.
9.
Nigam A, Li J, Fiasconaro M, Lin S, Capanu M, Kleiman D, et al.
Ann Surg Oncol
. 2023 Nov;
31(4):2337-2348.
PMID: 38036927
Background: The benefit of primary tumor resection in distant metastatic small bowel neuroendocrine tumors (SBNETs) is controversial, with treatment-based morbidity not well-defined. We aimed to determine the impact of primary...
10.
Nigam A, Xu B, Spanheimer P, Ganly I, Tuttle R, Wong R, et al.
Thyroid
. 2022 Aug;
32(10):1193-1200.
PMID: 35950622
Tumor grade is a new validated prognostic factor for medullary thyroid cancer (MTC). Calcitonin doubling time can predict MTC recurrence. We aimed to describe the association of tumor grade with...